GlassScriptPhysician profile
Karina Alas
NPI 1114270683
$2,879.64
in general payments reported to CMS, 2019-2025
19 companies · $89.85 in 2025
The $89.85 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $657 · 2022: $404 · 2023: $638 · 2024: $1,090 · 2025: $89.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,818.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $660.64 | 2021-2023 | Farxiga, Wainua |
| Janssen Pharmaceuticals, INC | $387.07 | 2021-2024 | Invega Sustenna, Xarelto |
| Abbvie INC. | $336.14 | 2021-2024 | |
| Pfizer INC. | $255.63 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $194.25 | 2021-2025 | Eliquis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $148.70 | 2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $140.44 | 2024 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Janssen Scientific Affairs, LLC | $136.33 | 2024 | Spravato |
| Neurocrine Biosciences, INC. | $134.86 | 2024 | Ingrezza |
| Glaxosmithkline, LLC. | $125.00 | 2023 | Nucala |
| Napo Pharmaceuticals INC | $121.42 | 2024 | Mytesi |
| Impulse Dynamics (USA) INC. | $48.71 | 2022-2023 | Optimizer |
| Paratek Pharmaceuticals, INC. | $42.30 | 2022 | |
| Axsome Therapeutics, INC. | $31.92 | 2024 | Auvelity |
| Kestra Medical Technology Services, INC. | $30.47 | 2023 | Assure Wcd |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $24.59 | 2024 | Lybalvi |
| Lexicon Pharmaceuticals, INC. | $22.60 | 2023 | Inpefa |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.52 | 2024 | |
| Novartis Pharmaceuticals Corporation | $17.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karina Alas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.